New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that has been developed by Defence Research and Development Organisation (DRDO) and been given an emergency use nod by Drugs Controller General of India’s (DCGI), was first studied by Patanjali researchers, claimed Acharya Balkrishna on Sunday (May 9, 2021).
A day after the DCGI granted permission for the Emergency Use of this drug as an adjunct remedy in average to extreme COVID-19 sufferers, Acharya Balkrishna mentioned, “We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.”
Balkrishna, MD of Patanjali Ayurved Ltd and co-founder of Patanjali Yogpeeth in Haridwar, additionally shared an image of his analysis paper, co-authored with three different researchers.
We take Immense Pride that #Patanjali has been the Pioneer Centre-stone for a lot of the researches performed for COVID-19 https://t.co/fCAPuORUJR pic.twitter.com/yQaMl1tqlh
— Acharya Balkrishna (@Ach_Balkrishna) May 9, 2021
Yoga guru Swami Ramdev additionally expressed, “Proud of Patanjali being the first in every research on COVID-19.”
#Corona की हर रिसर्च में पतंजलि के सबसे पहले होने का हमे गर्व है।@Ach_Balkrishna #CoronaPandemic https://t.co/W2AYGVUMHe
— स्वामी रामदेव (@yogrishiramdev) May 8, 2021
Link to the paper the place Patanjali Research Institute was the first one to counsel use of 2DG https://t.co/X8h2rQFfxL
— Monica (@ReallyMonica) May 8, 2021
This is to be famous that the therapeutic software of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Hyderabad-based Dr Reddy’s Laboratories (DRL).
Clinical trial outcomes have proven that this molecule helps in quicker restoration of hospitalised sufferers and reduces supplemental oxygen dependence and that the upper proportion of sufferers handled with 2-DG confirmed RT-PCR unfavorable conversion in COVID-19 sufferers.
“The drug will be of immense benefit to the people suffering from COVID-19,” mentioned the Ministry of Defence.
In April 2020, through the first wave of coronavirus, INMAS-DRDO scientists performed laboratory experiments with the assistance of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad and located that this molecule works successfully in opposition to the SARS-CoV-2 virus and inhibits viral progress. Based on these outcomes, DCGI CDSCO permitted a Phase-II scientific trial of 2-DG in COVID-19 sufferers in May 2020.
The DRDO, together with its trade companion DRL began scientific trials to check the protection and efficacy of the drug in COVID-19 sufferers. In Phase-II trials (together with dose-ranging) performed from May to October 2020, the drug was discovered to be protected in COVID-19 sufferers and confirmed vital enchancment of their restoration. Phase IIa was performed in six hospitals and Phase IIb (dose-ranging) scientific trial was performed at 11 hospitals all around the nation. Phase-II trial was performed on 110 sufferers.
